Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
IDE275 (GSK959) development is progressing into First-in-Human Phase 1 clinical trial(s) for the treatment of MSI-High solid tumors, representing IDEAYA's 5th potential first-in-class clinical program
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'
09:30am, Saturday, 26'th Oct 2024
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company's diversified portfolio in
GSK looking to moveon from Zantac in forthcoming update
06:03am, Friday, 25'th Oct 2024
GSK PLC (LSE:GSK, NYSE:GSK) share price bump on settlement of most of its Zantac litigation claims has reversed recently on concerns about two key products, Arexvy and Shingrix, in the important US ma
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--New data for AREXVY, GSK's RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease.
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for
11:06am, Wednesday, 23'rd Oct 2024
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK has earnings estimate cut, slow shingles vaccine uptake cited
09:16am, Monday, 21'st Oct 2024
UBS has cut its earnings per share (EPS) estimate for GSK PLC (LSE:GSK, NYSE:GSK) by 5% for fiscal years 2024 and 2025. The decision comes ahead of GSK's third-quarter results, expected on 30 October,
GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review
01:11pm, Thursday, 17'th Oct 2024
The FDA accepts and grants priority review to GSK's NDA for gepotidacin for treating uncomplicated urinary tract infections. A decision is due on March 26, 2025.
3 Vaccine Stocks to Watch as Flu Season Approaches
02:54pm, Wednesday, 16'th Oct 2024
Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring.
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)
02:15pm, Tuesday, 15'th Oct 2024
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals
12:55pm, Tuesday, 15'th Oct 2024
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.
GlaxoSmithKline sues Moderna for US patent infringement over COVID vaccines
10:20am, Tuesday, 15'th Oct 2024
GlaxoSmithKline sued Moderna in Delaware federal court on Tuesday for allegedly violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax.
BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni
07:30am, Tuesday, 15'th Oct 2024
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligen
GSK hails phase III nasal polyps success
02:51am, Monday, 14'th Oct 2024
GSK PLC (LSE:GSK, NYSE:GSK) has shared promising results from two major clinical trials (ANCHOR-1 and ANCHOR-2) testing its new treatment, depemokimab, for people suffering from chronic rhinosinusitis
GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy
11:46am, Thursday, 10'th Oct 2024
New data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV seasons in adults aged 60 years and above.
GSK: The Worst Is Finally Over (Rating Upgrade)
11:13am, Thursday, 10'th Oct 2024
GSK's share price surged 6% yesterday in the biggest rise seen since December 2022, after the company settled 93% of cases related to the Zantac litigation. The settlement will be reflected in Q3 2024
